199 related articles for article (PubMed ID: 34069498)
61. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer.
Jaouen G; Top S; Vessières A; Leclercq G; McGlinchey MJ
Curr Med Chem; 2004 Sep; 11(18):2505-17. PubMed ID: 15379709
[TBL] [Abstract][Full Text] [Related]
62. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
Levenson AS; MacGregor Schafer JI; Bentrem DJ; Pease KM; Jordan VC
J Steroid Biochem Mol Biol; 2001; 76(1-5):61-70. PubMed ID: 11384864
[TBL] [Abstract][Full Text] [Related]
63. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
64. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
[TBL] [Abstract][Full Text] [Related]
65. [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues].
Jirecek S; Pavo I; Huber JC
Gynakol Geburtshilfliche Rundsch; 1999; 39(4):184-90. PubMed ID: 10629380
[TBL] [Abstract][Full Text] [Related]
66. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
67. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
68. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
69. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
71. Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.
Asare BK; Yawson E; Rajnarayanan RV
Cell Cycle; 2017 Aug; 16(15):1465-1477. PubMed ID: 28723234
[TBL] [Abstract][Full Text] [Related]
72. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
73. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
74. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.
Laïos I; Journe F; Laurent G; Nonclercq D; Toillon RA; Seo HS; Leclercq G
J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):207-21. PubMed ID: 14672741
[TBL] [Abstract][Full Text] [Related]
75. Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
Nagel SC; Hagelbarger JL; McDonnell DP
Endocrinology; 2001 Nov; 142(11):4721-8. PubMed ID: 11606437
[TBL] [Abstract][Full Text] [Related]
76. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
77. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
78. Effect of selective estrogen receptor modulators on metabolic homeostasis.
Xu B; Lovre D; Mauvais-Jarvis F
Biochimie; 2016 May; 124():92-97. PubMed ID: 26133657
[TBL] [Abstract][Full Text] [Related]
79. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
80. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
